Rituximab

Off-label use of rituximab in dermatology: pemphigus treatment

(2013) Lislaine Bomm et al.   ANAIS BRASILEIROS DE DERMATOLOGIA

Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity

(2013) D. Rudnicka et al.   BLOOD

Approval of the first biosimilar antibodies in Europe

(2013) Alain Beck et al.   mAbs

Orphan drug development: an economically viable strategy for biopharma R&D

(2012) Kiran N. Meekings et al.   DRUG DISCOVERY TODAY

Novel CD20 monoclonal antibodies for lymphoma therapy

(2012) Shundong Cang et al.   Journal of Hematology & Oncology

The Cabilly patents

(2012) Ulrich Storz   mAbs

Approval on a knife edge

(2012) Michael Eisenstein   NATURE BIOTECHNOLOGY

Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope

(2012) Colin G Sandercock et al.   NATURE BIOTECHNOLOGY

Next generation and biosimilar monoclonal antibodies: Essential considerations towards regulatory acceptance in Europe; February 3-4, 2011; Freiburg, Germany

(2011) Janice M. Reichert   mAbs

Off-Label Use of Rituximab in a Multipayer Insurance System

(2011) Eliezer M. Van Allen et al.   Journal of Oncology Practice